Does the media favor ACAD or ADMA?

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than ADMA Biologics. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat ACADIA Pharmaceuticals' score of 1.16 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ADMA or ALLO?

In the previous week, Allogene Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for Allogene Therapeutics and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat Allogene Therapeutics' score of 0.92 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADMA or APGE?

In the previous week, Apogee Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for Apogee Therapeutics and 6 mentions for ADMA Biologics. Apogee Therapeutics' average media sentiment score of 1.64 beat ADMA Biologics' score of 1.17 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, TGTX or ADMA?

TG Therapeutics has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $799.54M 10.32 $447.18M $2.74 19.68 ADMA Biologics $510.17M 4.10 $146.93M $0.70 13.34

Does the media favor TGTX or ADMA?

In the previous week, TG Therapeutics had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for TG Therapeutics and 6 mentions for ADMA Biologics. TG Therapeutics' average media sentiment score of 1.19 beat ADMA Biologics' score of 1.17 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, IBRX or ADMA?

ADMA Biologics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 75.31 -$351.40M -$0.97 N/A ADMA Biologics $510.17M 4.10 $146.93M $0.70 13.34

Does the media favor IBRX or ADMA?

In the previous week, ImmunityBio had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat ImmunityBio's score of 0.61 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADMA Biologics (ADMA) Competitors

$9.34 -0.14 (-1.48%)

As of 08/28/2026 04:00 PM Eastern

Compare

ADMA vs. ACAD, ALLO, APGE, TGTX, and IBRX

Should you buy ADMA Biologics stock or one of its competitors? ADMA Biologics's main competitors and comparable companies include ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), Apogee Therapeutics (APGE), TG Therapeutics (TGTX), and ImmunityBio (IBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11
ADMA Biologics	$510.17M	4.10	$146.93M	$0.70	13.34

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to ADMA Biologics' net margin of 32.98%. ADMA Biologics' return on equity of 40.17% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
ADMA Biologics	32.98%	40.17%	26.97%

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than ADMA Biologics. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat ACADIA Pharmaceuticals' score of 1.16 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals currently has a consensus target price of $34.36, indicating a potential upside of 18.04%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 99.86%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ACADIA Pharmaceuticals has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats ADMA Biologics on 11 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Allogene Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

In the previous week, Allogene Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for Allogene Therapeutics and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat Allogene Therapeutics' score of 0.92 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 99.86%. Allogene Therapeutics has a consensus target price of $8.30, suggesting a potential upside of 310.89%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

ADMA Biologics has a net margin of 32.98% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Allogene Therapeutics	N/A	-50.04%	-36.74%

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.10	$146.93M	$0.70	13.34
Allogene Therapeutics	$4.64M	150.41	-$190.89M	-$0.67	N/A

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ADMA Biologics beats Allogene Therapeutics on 9 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Apogee Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

ADMA Biologics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.10	$146.93M	$0.70	13.34
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

ADMA Biologics presently has a consensus target price of $18.67, indicating a potential upside of 99.86%. Apogee Therapeutics has a consensus target price of $126.77, indicating a potential downside of 6.07%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe ADMA Biologics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Apogee Therapeutics had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 11 mentions for Apogee Therapeutics and 6 mentions for ADMA Biologics. Apogee Therapeutics' average media sentiment score of 1.64 beat ADMA Biologics' score of 1.17 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics has a net margin of 32.98% compared to Apogee Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Summary

ADMA Biologics beats Apogee Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

TG Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

In the previous week, TG Therapeutics had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 8 mentions for TG Therapeutics and 6 mentions for ADMA Biologics. TG Therapeutics' average media sentiment score of 1.19 beat ADMA Biologics' score of 1.17 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics presently has a consensus price target of $63.00, suggesting a potential upside of 16.82%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 99.86%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

TG Therapeutics has a net margin of 55.22% compared to ADMA Biologics' net margin of 32.98%. TG Therapeutics' return on equity of 73.49% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
ADMA Biologics	32.98%	40.17%	26.97%

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$799.54M	10.32	$447.18M	$2.74	19.68
ADMA Biologics	$510.17M	4.10	$146.93M	$0.70	13.34

Summary

TG Therapeutics beats ADMA Biologics on 14 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

ADMA Biologics has a net margin of 32.98% compared to ImmunityBio's net margin of -598.55%. ADMA Biologics' return on equity of 40.17% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
ADMA Biologics	32.98%	40.17%	26.97%

In the previous week, ImmunityBio had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.17 beat ImmunityBio's score of 0.61 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADMA Biologics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	75.31	-$351.40M	-$0.97	N/A
ADMA Biologics	$510.17M	4.10	$146.93M	$0.70	13.34

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 76.40%. ADMA Biologics has a consensus price target of $18.67, suggesting a potential upside of 99.86%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ImmunityBio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

ADMA Biologics beats ImmunityBio on 11 of the 16 factors compared between the two stocks.

Get ADMA Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADMA vs. The Competition

Export

Metric	ADMA Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	13.34	11.62	273.16	25.45
Price / Sales	4.10	1,295.87	605.06	76.64
Price / Cash	14.28	106.39	76.74	53.00
Price / Book	5.13	16.53	12.98	6.14
Net Income	$146.93M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-5.08%	-0.31%	0.13%	-0.80%
1 Month Performance	7.73%	9.80%	7.08%	4.13%
1 Year Performance	-45.89%	55.66%	24.67%	15.17%

ADMA Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADMA ADMA Biologics	3.6607 of 5 stars	$9.34 -1.5%	$18.67 +99.9%	-45.9%	$2.09B	$510.17M	13.34	530
ACAD ACADIA Pharmaceuticals	4.6828 of 5 stars	$29.65 +0.5%	$34.19 +15.3%	+12.0%	$5.08B	$1.07B	13.36	510	Positive News Analyst Forecast
ALLO Allogene Therapeutics	2.272 of 5 stars	$2.03 -2.9%	$8.30 +308.9%	+78.8%	$722.08M	$20K	N/A	310	Analyst Upgrade
APGE Apogee Therapeutics	1.6418 of 5 stars	$134.79 +0.0%	$124.43 -7.7%	+271.1%	$8.38B	N/A	N/A	91	News Coverage Positive News
TGTX TG Therapeutics	3.451 of 5 stars	$56.01 +3.2%	$63.00 +12.5%	+83.9%	$8.31B	$616.29M	20.44	290	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADMA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, APGE, TGTX, and IBRX

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Summary

How does ADMA Biologics compare to Apogee Therapeutics?

Summary

How does ADMA Biologics compare to TG Therapeutics?

Summary

How does ADMA Biologics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, APGE, TGTX, and IBRX

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Which has preferable earnings & valuation, ACAD or ADMA?

Do insiders and institutionals believe in ACAD or ADMA?

Is ACAD or ADMA more profitable?

Does the media favor ACAD or ADMA?

Do analysts recommend ACAD or ADMA?

Which has more volatility & risk, ACAD or ADMA?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Does the media refer more to ADMA or ALLO?

Which has more risk and volatility, ADMA or ALLO?

Do analysts prefer ADMA or ALLO?

Is ADMA or ALLO more profitable?

Which has stronger valuation and earnings, ADMA or ALLO?

Do insiders & institutionals have more ownership in ADMA or ALLO?

Summary

How does ADMA Biologics compare to Apogee Therapeutics?

Which has more volatility and risk, ADMA or APGE?

Which has preferable earnings and valuation, ADMA or APGE?

Do analysts rate ADMA or APGE?

Does the media prefer ADMA or APGE?

Do institutionals and insiders believe in ADMA or APGE?

Is ADMA or APGE more profitable?

Summary

How does ADMA Biologics compare to TG Therapeutics?

Which has more risk and volatility, TGTX or ADMA?

Does the media favor TGTX or ADMA?

Do analysts prefer TGTX or ADMA?

Is TGTX or ADMA more profitable?

Do insiders and institutionals hold more shares of TGTX or ADMA?

Which has preferable earnings and valuation, TGTX or ADMA?

Summary

How does ADMA Biologics compare to ImmunityBio?

Is IBRX or ADMA more profitable?

Does the media favor IBRX or ADMA?

Which has preferable earnings & valuation, IBRX or ADMA?

Do analysts rate IBRX or ADMA?

Do insiders and institutionals believe in IBRX or ADMA?

Which has more volatility & risk, IBRX or ADMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools